216 related articles for article (PubMed ID: 22425607)
1. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2015 Jun; 151(2):251-9. PubMed ID: 25917869
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Zhou W; Chen S; Xu F; Zeng X
World J Surg Oncol; 2018 Jul; 16(1):144. PubMed ID: 30007402
[TBL] [Abstract][Full Text] [Related]
5. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Bonilla L; Ben-Aharon I; Vidal L; Gafter-Gvili A; Leibovici L; Stemmer SM
J Natl Cancer Inst; 2010 Dec; 102(24):1845-54. PubMed ID: 21098761
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
7. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
Goldvaser H; Majeed H; Ribnikar D; Šeruga B; Ocaña A; Cescon DW; Amir E
Breast Cancer Res Treat; 2018 Jun; 169(3):413-425. PubMed ID: 29423899
[TBL] [Abstract][Full Text] [Related]
8. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
[TBL] [Abstract][Full Text] [Related]
9. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F; Ceppi M; Lambertini M; Bruzzi P; Ugolini D; Bighin C; Levaggi A; Giraudi S; D'Alonzo A; Vaglica M; Blondeaux E; Sertoli MR; Pronzato P; Del Mastro L
Breast; 2017 Jun; 33():104-108. PubMed ID: 28360014
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Chen G; Guo Z; Liu M; Yao G; Dong J; Guo J; Ye C
Oncol Res; 2017 Nov; 25(9):1567-1578. PubMed ID: 28337954
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S
J Clin Oncol; 2008 Jan; 26(1):44-53. PubMed ID: 18165639
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Zhang ZC; Xu QN; Lin SL; Li XY
PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
[TBL] [Abstract][Full Text] [Related]
15. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
Chen L; Zhou W; Hu X; Yi M; Ye C; Yao G
Cancer Treat Rev; 2019 May; 75():12-19. PubMed ID: 30856373
[TBL] [Abstract][Full Text] [Related]
16. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
18. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
19. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
Gyawali B; Niraula S
Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
